benzylpenicillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, 6-aminopenicillanic acid derivatives	2082	61-33-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: penicillin g benzylpenicillin benzylpenicillin G free penicillin G benzylpenicillinic acid penicillin G potassium penicillin penicillin G sodium benzylpenicillin potassium benzylpenicillin sodium	A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Molecular weight: 334.39 Formula: C16H18N2O4S CLOGP: 1.75 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 86.71 ALOGS: -3.07 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

penicillin g
benzylpenicillin
benzylpenicillin G
free penicillin G
benzylpenicillinic acid
penicillin G potassium
penicillin
penicillin G sodium
benzylpenicillin potassium
benzylpenicillin sodium

A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)

Molecular weight: 334.39
Formula: C16H18N2O4S
CLOGP: 1.75
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 86.71
ALOGS: -3.07
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3.60	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	564.67 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.24 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	6.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.40 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.70 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	2.68 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Feb. 6, 1947	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	1583.91	16.31	879	11166	309808	63167169
Loss of employment	151.35	16.31	42	12003	2202	63474775
Anaphylactic reaction	148.38	16.31	113	11932	65987	63410990
Urticaria	134.04	16.31	161	11884	165641	63311336
Oesophageal spasm	124.95	16.31	39	12006	3084	63473893
Lymphoedema	123.92	16.31	55	11990	11637	63465340
Oesophageal pain	122.47	16.31	40	12005	3661	63473316
Rash	101.54	16.31	283	11762	560588	62916389
Sleep apnoea syndrome	70.18	16.31	52	11993	29081	63447896
Lipase increased	69.30	16.31	35	12010	9865	63467112
Hepatic steatosis	68.52	16.31	51	11994	28718	63448259
Gastric disorder	64.86	16.31	55	11990	37314	63439663
Cystitis	50.32	16.31	57	11988	54934	63422043
Pneumococcal infection	47.31	16.31	12	12033	443	63476534
Tinnitus	47.13	16.31	45	12000	35583	63441394
Hepatitis infectious mononucleosis	45.07	16.31	9	12036	108	63476869
Abdominal pain upper	44.01	16.31	111	11934	206333	63270644
Hallucination	42.16	16.31	52	11993	54765	63422212
Migraine	36.27	16.31	68	11977	103278	63373699
Eczema herpeticum	36.19	16.31	8	12037	161	63476816
Hypersensitivity	35.49	16.31	129	11916	292556	63184421
Pancreatitis	35.28	16.31	45	12000	49010	63427967
Toxic epidermal necrolysis	33.50	16.31	32	12013	25302	63451675
Fibromyalgia	33.46	16.31	57	11988	80363	63396614
Drug intolerance	33.26	16.31	131	11914	308530	63168447
Lipoedema	31.68	16.31	8	12037	290	63476687
Dysbiosis	30.81	16.31	10	12035	896	63476081
Exposure during pregnancy	30.41	16.31	81	11964	155466	63321511
Bronchial obstruction	29.44	16.31	11	12034	1496	63475481
Angioedema	28.37	16.31	40	12005	47925	63429052
Agitation	27.05	16.31	44	12001	59713	63417264
Fall	26.98	16.31	21	12024	392313	63084664
Pruritus	26.58	16.31	137	11908	361316	63115661
Infusion related reaction	26.38	16.31	7	12038	245514	63231463
Alopecia	24.58	16.31	17	12028	337519	63139458
Cough	24.39	16.31	115	11930	292628	63184349
Systemic lupus erythematosus	24.33	16.31	5	12040	208913	63268064
Cardiac failure congestive	24.33	16.31	54	11991	92379	63384598
Malaise	24.18	16.31	148	11897	415806	63061171
Glossodynia	23.70	16.31	3	12042	178873	63298104
Idiosyncratic drug reaction	23.60	16.31	8	12037	820	63476157
Fluid retention	23.11	16.31	41	12004	59645	63417332
Type IV hypersensitivity reaction	22.51	16.31	11	12034	2887	63474090
Tendon operation	21.60	16.31	6	12039	315	63476662
Oligohydramnios	21.52	16.31	14	12031	6352	63470625
Fistula discharge	21.43	16.31	8	12037	1085	63475892
Vision blurred	21.21	16.31	51	11994	91873	63385104
Anaemia neonatal	21.14	16.31	6	12039	341	63476636
Feeling abnormal	21.08	16.31	69	11976	148323	63328654
Wound	21.00	16.31	3	12042	163260	63313717
Spinal cord disorder	20.20	16.31	8	12037	1273	63475704
Administration site bruise	19.93	16.31	6	12039	420	63476557
Joint swelling	19.56	16.31	20	12025	327646	63149331
Phlebectomy	19.53	16.31	4	12041	55	63476922
Wrist surgery	19.36	16.31	7	12038	868	63476109
Upper limb fracture	17.91	16.31	20	12025	18948	63458029
Bladder spasm	17.63	16.31	8	12037	1780	63475197
Carcinogenicity	17.18	16.31	3	12042	16	63476961
Death	17.04	16.31	28	12017	374353	63102624
Myelopathy	16.92	16.31	9	12036	2817	63474160
Pharyngeal swelling	16.70	16.31	12	12033	6392	63470585
Gonorrhoea	16.51	16.31	4	12041	122	63476855
Skin reaction	16.38	16.31	17	12028	14832	63462145
Anxiety	16.33	16.31	83	11962	217458	63259519

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	445.90	17.85	255	7453	80274	34868949
Spinal muscular atrophy	110.92	17.85	24	7684	372	34948851
Pneumococcal sepsis	99.64	17.85	27	7681	1110	34948113
Sleep disorder due to general medical condition, insomnia type	95.73	17.85	27	7681	1289	34947934
Rheumatoid arthritis	93.27	17.85	73	7635	38165	34911058
Motor neurone disease	78.34	17.85	19	7689	498	34948725
Increased bronchial secretion	77.93	17.85	25	7683	1856	34947367
Sputum increased	76.15	17.85	26	7682	2344	34946879
Ischaemic cerebral infarction	74.71	17.85	22	7686	1225	34947998
Stoma closure	73.05	17.85	16	7692	263	34948960
Respiratory tract infection bacterial	71.03	17.85	23	7685	1759	34947464
Disease complication	68.75	17.85	25	7683	2711	34946512
Oral surgery	66.01	17.85	17	7691	572	34948651
Oral disorder	64.73	17.85	27	7681	4222	34945001
Chest X-ray abnormal	63.83	17.85	27	7681	4371	34944852
Bronchial disorder	63.71	17.85	20	7688	1383	34947840
Resuscitation	63.03	17.85	20	7688	1433	34947790
Lymphadenectomy	62.64	17.85	15	7693	372	34948851
Cellulitis enterococcal	62.16	17.85	12	7696	101	34949122
Lower respiratory tract infection bacterial	58.79	17.85	15	7693	486	34948737
Metabolic disorder	57.88	17.85	25	7683	4258	34944965
Lung consolidation	53.06	17.85	26	7682	5910	34943313
Acute generalised exanthematous pustulosis	52.68	17.85	27	7681	6749	34942474
Brain injury	52.22	17.85	26	7682	6116	34943107
Cerebral ischaemia	48.60	17.85	25	7683	6297	34942926
Jarisch-Herxheimer reaction	46.98	17.85	13	7695	578	34948645
Scoliosis	46.79	17.85	19	7689	2774	34946449
Intestinal ischaemia	46.39	17.85	26	7682	7768	34941455
Motor dysfunction	46.29	17.85	25	7683	6949	34942274
Tachypnoea	44.62	17.85	35	7673	18317	34930906
Demyelination	44.18	17.85	19	7689	3202	34946021
Muscle atrophy	39.51	17.85	23	7685	7381	34941842
Chest discomfort	36.27	17.85	52	7656	54478	34894745
Middle insomnia	35.95	17.85	21	7687	6781	34942442
Atelectasis	35.09	17.85	30	7678	17697	34931526
Proteus infection	35.01	17.85	12	7696	1094	34948129
Drug intolerance	32.78	17.85	52	7656	59518	34889705
Marrow hyperplasia	30.61	17.85	11	7697	1152	34948071
Ureterolithiasis	30.02	17.85	13	7695	2226	34946997
Pain in jaw	29.83	17.85	24	7684	13016	34936207
Rheumatoid nodule	29.64	17.85	14	7694	2933	34946290
Drug reaction with eosinophilia and systemic symptoms	28.88	17.85	36	7672	32976	34916247
Radiation fibrosis - lung	28.86	17.85	5	7703	21	34949202
Clonal haematopoiesis	28.70	17.85	6	7702	78	34949145
Differential white blood cell count abnormal	28.18	17.85	11	7697	1448	34947775
Secretion discharge	28.00	17.85	17	7691	5888	34943335
Osteomyelitis salmonella	27.52	17.85	5	7703	29	34949194
Myelofibrosis	27.12	17.85	11	7697	1600	34947623
Death	25.78	17.85	30	7678	398019	34551204
Injury	25.61	17.85	27	7681	20660	34928563
Mechanical ventilation	24.99	17.85	11	7697	1959	34947264
Coombs positive haemolytic anaemia	24.86	17.85	9	7699	963	34948260
Splenic infarction	24.44	17.85	11	7697	2064	34947159
Circulatory collapse	23.48	17.85	26	7682	21012	34928211
Endotracheal intubation	23.21	17.85	12	7696	3053	34946170
Impaired work ability	23.12	17.85	16	7692	6914	34942309
Skin mass	22.91	17.85	13	7695	3972	34945251
Hypersensitivity	22.84	17.85	45	7663	60990	34888233
Synovitis	22.29	17.85	21	7687	14045	34935178
Urticaria	22.16	17.85	45	7663	62332	34886891
Mean platelet volume increased	21.77	17.85	7	7701	523	34948700
C-reactive protein decreased	21.65	17.85	10	7698	1992	34947231
Biopsy liver	21.46	17.85	6	7702	277	34948946
Oedema peripheral	20.95	17.85	66	7642	119746	34829477
Wound infection	20.51	17.85	15	7693	7064	34942159
Respiratory arrest	20.50	17.85	28	7680	28015	34921208
Lung infiltration	19.94	17.85	19	7689	12886	34936337
Inflammation	18.82	17.85	27	7681	28268	34920955
Lymphadenitis	18.47	17.85	9	7699	2019	34947204
Toxicity to various agents	17.96	17.85	11	7697	200351	34748872

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	1060.59	14.98	686	15254	298230	79430218
Loss of employment	143.25	14.98	42	15898	2545	79725903
Oesophageal spasm	131.26	14.98	42	15898	3414	79725034
Anaphylactic reaction	129.51	14.98	118	15822	83625	79644823
Oesophageal pain	126.36	14.98	43	15897	4236	79724212
Urticaria	120.63	14.98	166	15774	185035	79543413
Lymphoedema	117.99	14.98	55	15885	12358	79716090
Spinal muscular atrophy	107.15	14.98	23	15917	380	79728068
Pneumococcal sepsis	92.10	14.98	27	15913	1635	79726813
Rash	84.15	14.98	280	15660	578078	79150370
Motor neurone disease	77.12	14.98	19	15921	589	79727859
Stoma closure	72.98	14.98	16	15924	293	79728155
Hepatic steatosis	69.98	14.98	59	15881	37679	79690769
Respiratory tract infection bacterial	65.77	14.98	22	15918	2055	79726393
Sleep apnoea syndrome	65.53	14.98	56	15884	36422	79692026
Increased bronchial secretion	62.75	14.98	24	15916	3303	79725145
Ischaemic cerebral infarction	57.73	14.98	21	15919	2514	79725934
Disease complication	56.81	14.98	25	15915	4912	79723536
Gastric disorder	56.36	14.98	52	15888	37381	79691067
Sputum increased	55.16	14.98	24	15916	4589	79723859
Bronchial disorder	54.39	14.98	20	15920	2469	79725979
Chest X-ray abnormal	54.17	14.98	28	15912	7855	79720593
Oral surgery	52.53	14.98	16	15924	1105	79727343
Resuscitation	51.36	14.98	19	15921	2385	79726063
Lower respiratory tract infection bacterial	50.64	14.98	15	15925	941	79727507
Migraine	50.33	14.98	74	15866	87419	79641029
Cystitis	49.81	14.98	57	15883	52675	79675773
Toxic epidermal necrolysis	46.94	14.98	51	15889	44530	79683918
Lymphadenectomy	46.57	14.98	15	15925	1244	79727204
Lung consolidation	45.40	14.98	26	15914	8921	79719527
Abdominal pain upper	45.32	14.98	122	15818	223697	79504751
Tinnitus	43.71	14.98	49	15891	44284	79684164
Malaise	43.27	14.98	203	15737	489666	79238782
Oral disorder	42.49	14.98	26	15914	10069	79718379
Hepatitis infectious mononucleosis	41.91	14.98	9	15931	149	79728299
Metabolic disorder	39.58	14.98	24	15916	9146	79719302
Drug reaction with eosinophilia and systemic symptoms	39.37	14.98	56	15884	64188	79664260
Brain injury	39.35	14.98	26	15914	11491	79716957
Type IV hypersensitivity reaction	38.52	14.98	18	15922	4063	79724385
Tachypnoea	37.87	14.98	39	15901	32024	79696424
Pneumococcal infection	37.85	14.98	12	15928	946	79727502
Angioedema	36.28	14.98	59	15881	75976	79652472
Cerebral ischaemia	35.20	14.98	24	15916	11171	79717277
Fibromyalgia	34.97	14.98	53	15887	64287	79664161
Drug intolerance	33.98	14.98	123	15817	263996	79464452
Jarisch-Herxheimer reaction	33.77	14.98	11	15929	946	79727502
Intestinal ischaemia	33.75	14.98	25	15915	13245	79715203
Cellulitis enterococcal	32.05	14.98	6	15934	47	79728401
Acute generalised exanthematous pustulosis	32.03	14.98	27	15913	17227	79711221
Death	31.78	14.98	40	15900	566474	79161974
Eczema herpeticum	31	14.98	8	15932	300	79728148
Scoliosis	30.84	14.98	19	15921	7445	79721003
Toxicity to various agents	30.24	14.98	24	15916	421516	79306932
Hallucination	29.90	14.98	58	15882	85687	79642761
Demyelination	29.58	14.98	19	15921	8004	79720444
Motor dysfunction	29.31	14.98	24	15916	14709	79713739
Fall	28.86	14.98	33	15907	487596	79240852
Muscle atrophy	28.21	14.98	21	15919	11211	79717237
Marrow hyperplasia	27.93	14.98	11	15929	1637	79726811
Osteomyelitis salmonella	26.29	14.98	5	15935	43	79728405
Differential white blood cell count abnormal	25.47	14.98	11	15929	2066	79726382
Radiation fibrosis - lung	25.18	14.98	5	15935	55	79728393
Ureterolithiasis	24.53	14.98	13	15927	3835	79724613
Exposure during pregnancy	24.46	14.98	59	15881	101073	79627375
Coombs positive haemolytic anaemia	24.39	14.98	9	15931	1121	79727327
Administration site bruise	24.08	14.98	6	15934	195	79728253
Myelofibrosis	23.51	14.98	11	15929	2489	79725959
Fluid retention	22.86	14.98	46	15894	69763	79658685
Vision blurred	22.69	14.98	59	15881	105839	79622609
Joint swelling	22.55	14.98	15	15925	288631	79439817
Mechanical ventilation	22.46	14.98	11	15929	2753	79725695
Bronchial obstruction	22.44	14.98	11	15929	2757	79725691
Splenic infarction	22.29	14.98	12	15928	3652	79724796
Rash maculo-papular	22.12	14.98	40	15900	56038	79672410
Circulatory collapse	21.85	14.98	32	15908	37636	79690812
Contraindicated product administered	21.64	14.98	75	15865	157463	79570985
Dysbiosis	20.18	14.98	8	15932	1211	79727237
Pruritus	19.90	14.98	141	15799	394507	79333941
C-reactive protein decreased	19.85	14.98	10	15930	2658	79725790
Atelectasis	19.58	14.98	28	15912	32229	79696219
Endotracheal intubation	19.52	14.98	12	15928	4685	79723763
Idiosyncratic drug reaction	19.35	14.98	8	15932	1349	79727099
Lipoedema	18.67	14.98	5	15935	217	79728231
Administration site swelling	18.50	14.98	6	15934	509	79727939
Drug ineffective	18.26	14.98	310	15630	1080603	78647845
Agitation	17.83	14.98	52	15888	99663	79628785
Type I hypersensitivity	17.68	14.98	11	15929	4387	79724061
Tendon operation	17.38	14.98	5	15935	283	79728165
Biopsy liver	17.33	14.98	6	15934	622	79727826
X-ray abnormal	17.18	14.98	12	15928	5801	79722647
Alopecia	16.78	14.98	13	15927	231342	79497106
Cross sensitivity reaction	16.76	14.98	10	15930	3702	79724746
Pyrexia	16.72	14.98	208	15732	678501	79049947
Chest discomfort	16.64	14.98	63	15877	137981	79590467
Upper limb fracture	16.25	14.98	19	15921	17948	79710500
SJS-TEN overlap	16.22	14.98	6	15934	753	79727695
Urticaria contact	15.86	14.98	3	15937	25	79728423
Skin mass	15.76	14.98	13	15927	8050	79720398
Lung infiltration	15.57	14.98	21	15919	22891	79705557
Secretion discharge	15.48	14.98	17	15923	15005	79713443
Drug resistance	15.25	14.98	29	15911	42184	79686264

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01CE01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase sensitive penicillins
ATC	S01AA14	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
FDA CS	M0016152	Penicillins
FDA EPC	N0000175497	Penicillin-class Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:50904	alergeno
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:53000	epitope role
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rat bite fever	indication	1685005
Acute otitis media	indication	3110003
Meningococcemia	indication	4089001
Streptococcal meningitis	indication	4510004	DOID:11574
Gangrenous pneumonia	indication	7063008
Inhalational anthrax	indication	11389007
Actinomycotic infection	indication	11817007	DOID:8478
Anthrax septicemia	indication	14972006
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Gingivostomatitis	indication	20607006
Pulmonary actinomycosis	indication	21846001
Pinta	indication	22064009	DOID:1022
Cervicofacial actinomycosis	indication	23014006
Neurosyphilis	indication	26039008	DOID:9988
Gonococcal conjunctivitis neonatorum	indication	28438004
Scarlet fever	indication	30242009	DOID:8596
Listeria meningitis	indication	31568009	DOID:11572
Pneumonia due to Streptococcus	indication	34020007
Congenital syphilis	indication	35742006	DOID:9856
Streptococcal tonsillitis	indication	41582007
Abdominal actinomycosis	indication	43894001
Erysipelas	indication	44653001	DOID:11330
Gonococcal infection of joint	indication	44743006
Pneumococcal meningitis	indication	51169003
Upper respiratory infection	indication	54150009
Yaws	indication	70647001	DOID:10371
Late syphilis	indication	72083004	DOID:8200
Abscess of lung	indication	73452002	DOID:0060317
Syphilis	indication	76272004
Tetanus	indication	76902006	DOID:11338
Pasteurella infection	indication	83172007	DOID:11055
Cutaneous anthrax	indication	84980006	DOID:7426
Streptococcal infectious disease	indication	85769006
Tertiary lesion of yaws	indication	88037009
Gastrointestinal anthrax	indication	111798006	DOID:13386
Listerial endocarditis	indication	186318004
Primary genital syphilis	indication	186847001
Latent early syphilis	indication	186867005
Late latent syphilis	indication	186903006
Latent yaws	indication	186973005
Meningococcal meningitis	indication	192644005
Infection by Pasteurella multocida	indication	197718007
Sepsis of the newborn	indication	206376005
Pneumococcal pneumonia	indication	233607000
Neonatal pneumonia	indication	233619008
Streptococcal toxic shock syndrome	indication	240451000
Secondary syphilis	indication	240557004	DOID:4157
Bejel	indication	240686008	DOID:13431
Gas gangrene caused by clostridium perfringens	indication	266093005
Neonatal meningitis	indication	276674008
Bacterial endocarditis	indication	301183007
Streptococcus pyogenes infection	indication	302809008
Septicemia due to enterococcus	indication	310669007
Infective otitis media	indication	312218008
Diphtheria	indication	397428000
Infection due to Clostridium botulinum	indication	398565003
Fusospirochetal pharyngitis	indication	399095008
Erysipeloid	indication	400105005
Pharyngitis	indication	405737000	DOID:2275
Infection due to Staphylococcus aureus	indication	406602003
Anthrax	indication	409498004	DOID:7427
Aspiration pneumonia	indication	422588002	DOID:3240
Latent syphilis	indication	444150000	DOID:9531
Streptococcus Myositis	indication
Disseminated Gonococcal Infection	indication
Tertiary Bejel	indication
Pneumococcal Acute Otitis Media	indication
Necrotizing Fasciitis Streptococcus Infection	indication
Upper Respiratory Infection due to Neisseria Meningitidis	indication
Streptococcus Empyema	indication
Pneumococcus Endocarditis	indication
Streptococcal Endocarditis	indication
Upper Respiratory Pneumococcal Infection	indication
Latent Bejel	indication
Upper Respiratory Streptococcal Infection	indication
Streptococcus Pericarditis	indication
Rheumatic Fever Prevention	indication
Clostridium Perfringens Empyema	indication
Neonatal Group B Streptococcal Septicemia	indication
Asymptomatic Congenital Syphilis	indication
Granulomatosis Infantiseptica	indication
Infection Prevention from Tooth Extraction	indication
Lyme disease	off-label use	23502006	DOID:11729
Lyme arthritis	off-label use	33937009
Neonatal conjunctivitis	off-label use	34298002	DOID:9699
Omphalitis of the newborn	off-label use	42052009
Lyme carditis	off-label use	77863005
Relapsing fever	off-label use	420079008	DOID:13034
Infection due to anaerobic bacteria	off-label use	423451008
Pneumococcal Infection Prevention in Sickle Cell Disease	off-label use
Lyme Disease of the Central Nervous System	off-label use
Kidney disease	contraindication	90708001	DOID:557
Infectious mononucleosis	contraindication	271558008	DOID:8568
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	No Use Class Stated Or Implied	Indication
Dogs	No Use Class Stated Or Implied	Indication
Turkeys	Erysipelas caused by Erysipelothrix rhusiopathiae	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Penicillin G Potassium, USP	Zoetis Inc.	1
Veesyn Granules for Oral Soln	Boehringer lngelheim Animal Health USA Inc.	1
PenAqua Sol-G, Penicillin G Potassium, USP	Bimeda Animal Health Limited	1
R-Pen	Huvepharma EOOD	1
Solu-Pen	Zoetis Inc.	1
Penicillin G Potassium USP	Quo Vademus LLC	1
Han-Pen	HQ Specialty Pharma Corp.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.79	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme	PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_CLOPE				WOMBAT-PK
Beta-lactamase TEM	Enzyme	BLAT_ECOLX		Ki	4.70	CHEMBL
Beta-lactamase	Enzyme	AMPC_ENTCL		IC50	5.44	CHEMBL

External reference:

ID	Source
4017440	VUID
N0000145828	NUI
D01053	KEGG_DRUG
113-98-4	SECONDARY_CAS_RN
69-57-8	SECONDARY_CAS_RN
4017435	VANDF
4017438	VANDF
4017440	VANDF
4019880	VANDF
C0030827	UMLSCUI
CHEBI:18208	CHEBI
PNN	PDB_CHEM_ID
CHEMBL29	ChEMBL_ID
DB01053	DRUGBANK_ID
CHEMBL1223	ChEMBL_ID
5904	PUBCHEM_CID
4796	IUPHAR_LIGAND_ID
203133	RXNORM
179173	MMSL
179425	MMSL
2147	MMSL
2169	MMSL
5245	MMSL
5247	MMSL
d00116	MMSL
d07728	MMSL
d07729	MMSL
002679	NDDF
002680	NDDF
004977	NDDF
016121	NDDF
11986009	SNOMEDCT_US
323389000	SNOMEDCT_US
373270004	SNOMEDCT_US
6369005	SNOMEDCT_US
764146007	SNOMEDCT_US
78507004	SNOMEDCT_US
89055006	SNOMEDCT_US
D010400	MESH_DESCRIPTOR_UI
D010406	MESH_DESCRIPTOR_UI
CHEMBL1126	ChEMBL_ID
58	INN_ID
Q42T66VG0C	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0420	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	26 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0420	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	26 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0420	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	26 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0430	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	26 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0430	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	26 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0430	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	26 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0520	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0520	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0520	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0520	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0520	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0520	POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0530	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0530	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0530	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0530	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0530	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	25 sections
Pfizerpen	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0530	POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	25 sections
PENICILLIN G POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1021	INJECTION, SOLUTION	1000000 [iU]	INTRAVENOUS	NDA	23 sections
PENICILLIN G POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1021	INJECTION, SOLUTION	1000000 [iU]	INTRAVENOUS	NDA	23 sections
PENICILLIN G POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1023	INJECTION, SOLUTION	2000000 [iU]	INTRAVENOUS	NDA	23 sections
PENICILLIN G POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1023	INJECTION, SOLUTION	2000000 [iU]	INTRAVENOUS	NDA	23 sections
PENICILLIN G POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1025	INJECTION, SOLUTION	3000000 [iU]	INTRAVENOUS	NDA	23 sections
PENICILLIN G POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1025	INJECTION, SOLUTION	3000000 [iU]	INTRAVENOUS	NDA	23 sections
Penicillin G Potassium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6135	INJECTION, POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	22 sections
Penicillin G Potassium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6136	INJECTION, POWDER, FOR SOLUTION	20000000 [iU]	INTRAVENOUS	ANDA	22 sections
Penicillin G Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6153	INJECTION, POWDER, FOR SOLUTION	5000000 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Penicillin G Potassium	HUMAN PRESCRIPTION DRUG LABEL	1	44567-310	INJECTION, POWDER, FOR SOLUTION	1000000 [iU]	INTRAVENOUS	ANDA	24 sections
Penicillin G Potassium	HUMAN PRESCRIPTION DRUG LABEL	1	44567-310	INJECTION, POWDER, FOR SOLUTION	1000000 [iU]	INTRAVENOUS	ANDA	24 sections
Penicillin G Potassium	HUMAN PRESCRIPTION DRUG LABEL	1	44567-311	INJECTION, POWDER, FOR SOLUTION	5000000 [iU]	INTRAVENOUS	ANDA	24 sections